Trial · NCT02358031
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pembrolizumab Monotherapy (Pembro Mono) | 301 | |
| Overall Study | STARTED | Pembrolizumab + Chemotherapy (Pembro Combo) | 281 | |
| Overall Study | STARTED | Cetuximab + Chemotherapy (Control) | 300 | |
| Overall Study | Treated | Pembrolizumab Monotherapy (Pembro Mono) | 300 | |
| Overall Study | Treated | Pembrolizumab + Chemotherapy (Pembro Combo) | 276 | |
| Overall Study | Treated | Cetuximab + Chemotherapy (Control) | 287 | |
| Overall Study | Pembro Mono v Control Efficacy Analyses | Pembrolizumab Monotherapy (Pembro Mono) | 301 | |
| Overall Study | Pembro Mono v Control Efficacy Analyses | Pembrolizumab + Chemotherapy (Pembro Combo) | 0 | |
| Overall Study | Pembro Mono v Control Efficacy Analyses | Cetuximab + Chemotherapy (Control) | 300 | |
| Overall Study | Pembro Combo v Control Efficacy Analyses | Pembrolizumab Monotherapy (Pembro Mono) | 0 | |
| Overall Study | Pembro Combo v Control Efficacy Analyses | Pembrolizumab + Chemotherapy (Pembro Combo) | 281 | |
| Overall Study | Pembro Combo v Control Efficacy Analyses | Cetuximab + Chemotherapy (Control) | 278 | |
| Overall Study | Received Second Course of Pembrolizumab | Pembrolizumab Monotherapy (Pembro Mono) | 8 | |
| Overall Study | Received Second Course of Pembrolizumab | Pembrolizumab + Chemotherapy (Pembro Combo) | 6 | |
| Overall Study | Received Second Course of Pembrolizumab | Cetuximab + Chemotherapy (Control) | 0 | |
| Overall Study | COMPLETED | Pembrolizumab Monotherapy (Pembro Mono) | 2 | |
| Overall Study | COMPLETED | Pembrolizumab + Chemotherapy (Pembro Combo) | 1 | |
| Overall Study | COMPLETED | Cetuximab + Chemotherapy (Control) | 0 | |
| Overall Study | NOT COMPLETED | Pembrolizumab Monotherapy (Pembro Mono) | 299 | |
| Overall Study | NOT COMPLETED | Pembrolizumab + Chemotherapy (Pembro Combo) | 280 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02358031/flow